Several constituents have written to me in the last couple of years about the availability of Orkambi for those with cystic fibrosis and I have raised their concerns with the Department of Health and Social Care.
I warmly welcome, therefore, the recent announcement that NHS England has secured an agreement with Vertex Pharmaceuticals to make available all three of their UK-licensed cystic fibrosis medicines. This will mean that all NHS patients will now have full access to Orkambi, Symkevi and Kalydeco, benefiting around 5,000 people.
I attach a letter from the Health Secretary with further details.
|20191025 - Dear Colleague Vertex_.docx||50.43 KB|